01/10/2010 Low MBL level increases risk of subclinical graft rejection 01/10/2010 Trying to identify early the group of patients at increased risk of subclinical rejection of the graft is one of the challenges to improve outcomes after transplantation, hence useful predictors markers are sought. The MBL (Mannose Binding Lectin) protein has emerged as one of these biomarkers, such that patients with low MBL levels at a higher risk of subclinical rejection and graft inflammation. This has been the subject of the conference by Daniel Seron, Chief of Nephrology at Hospital Vall d'Hebron, at the Second Symposium on Advances in Translational Transplant Immunology, held in Oviedo, in which also referred to innate immunity and chronic graft damage. Trying to identify early the group of patients at increased risk of subclinical rejection of the graft is one of the challenges to improve outcomes after transplantation, hence useful predictors markers are sought. The MBL (Mannose Binding Lectin) protein has emerged as one of these biomarkers, such that patients with low MBL levels at a higher risk of subclinical rejection and graft inflammation. This has been the subject of the conference by Daniel Seron, Chief of Nephrology at Hospital Vall d'Hebron, at the Second Symposium on Advances in Translational Transplant Immunology, held in Oviedo, in which also referred to innate immunity and chronic graft damage. Twitter LinkedIn Facebook Whatsapp
